What Happens to Public Health When the Money Runs Out?

“When the money runs out” is a provocative phrase. It does not mean that public health funding disappears overnight, or that every budget cut is automatically harmful. It means something more precise — and more uncomfortable. Across 2025 and 2026, governments, donors and European institutions have been cutting, freezing, redeploying or simply failing to lock in the money that keeps essential public health functions working: disease surveillance, laboratories and data systems, vaccination capacity, health promotion, outbreak response, emergency preparedness and the quieter work of preventing illness before it becomes demand for treatment. The question worth asking is not only how large the reductions are. It is what actually happens to population health when sustained funding pressure begins to weaken the systems designed to prevent disease, detect threats and protect communities.

A financing squeeze across systems — not only across aid budgets

The global aid story remains severe, and it still matters. According to the OECD’s June 2026 ODA outlook, net official development assistance from DAC countries fell by 23.3% in 2025 — described as the largest annual contraction on record — and is projected to fall a further 6.9% in 2026. Within that retreat, health faces some of the deepest cuts: net ODA for health and population services is projected to decline by 29–46% from 2024 to 2026, equivalent to roughly USD 5–8 billion, and to sit as much as 63% below its 2022 COVID-era peak. WHO’s own base programmes envelope for 2026–2027 was set at about USD 4.27 billion, down from about USD 4.97 billion in 2024–2025.

But reducing the whole debate to donor withdrawals would miss the deeper point. Public health financing pressure also appears inside national budgets, European programmes and institutional planning: as prevention share slips after emergency peaks, as earmarked project money fails to sustain laboratories and workforce posts, and as fiscal competition from ageing, debt service, defence and climate adaptation squeezes the quieter public-health lines. The World Bank’s November 2025 projections underline how uneven the exposure is globally — combined government and donor health spending is projected to fall by 2030 in about 80% of low-income countries and 40% of lower-middle-income countries as development assistance for health declines by around 20%. Europe faces a different arithmetic. The mechanism of pressure is less “aid running out” than prevention and preparedness competing badly for durable public money.

What losing public health capacity looks like in practice

Budget percentages become real when they change what a health authority can still do on a Tuesday morning. A financing decision rarely announces itself as “public health has collapsed.” More often it shows up as delayed laboratory reagents, fewer field epidemiologists available for an unexplained cluster, postponed refresher training, thinner health-promotion campaigns, longer gaps between surveillance reports, or a vaccination outreach team that no longer reaches the last villages in a schedule. In November 2025, WHO reported that external health aid was projected to drop by about 30–40% in 2025 compared with 2023, and that a March 2025 survey of 108 low- and middle-income countries linked funding cuts to reductions in critical services — including maternal care, vaccination, health emergency preparedness and response, and disease surveillance — by up to 70% in some countries. More than 50 countries reported job losses among health and care workers, alongside major disruptions to training.

OECD sector projections help explain why those frontline functions are so exposed where aid still pays for a large share of the work. Within health ODA, population and reproductive health — including HIV/AIDS and other STI control — faces projected cuts of up to about 54% from 2024 to 2026. Communicable-disease control is under acute pressure too: malaria control up to about 60%, tuberculosis up to about 57%, and other infectious-disease control up to about 40%. Those lines are not abstractions. They are case-finding, commodities, outreach teams and laboratory confirmation — the machinery that converts money into early detection and interrupted transmission.

Projected ODA declines from 2024 to 2026: malaria control up to 59.6%, tuberculosis up to 57.2%, population and reproductive health up to 54.1%, other infectious-disease control up to 40.4%.

Malaria control

−59.6%

Tuberculosis

−57.2%

Population & reproductive health

−54.1%

Other infectious-disease control

−40.4%

Source: OECD, ODA projections for 2026 and the near-term (June 2026). Figures are upper-end projected declines from 2024 to 2026.

Even where money is domestic rather than donor-funded, the practical sequence is similar. Underinvestment in NCD prevention does not empty a hospital overnight; it leaves health-promotion and screening systems thinner while treatment demand keeps rising. Weakened preparedness does not cancel an emergency plan on paper; it leaves stockpiles, surge staffing and rapid-response drills under-rehearsed. Data infrastructure that is not maintained does not announce its failure until the next outbreak arrives and nobody can see the signal clearly. The causal chain from financing to harm usually runs through capacity first — and only later through visible excess illness or crisis response.

The paradox of invisible success

Here lies the central political paradox. Prevention and preparedness often succeed by making things not happen: the outbreak contained before it spreads, the vaccine-preventable disease that never becomes a national emergency, the contaminated water source corrected before a mass diarrhoeal event, the heat-health warning that keeps emergency departments from tipping over. Treatment demand, by contrast, arrives with patients, waiting lists and immediate political pressure. When fiscal space shrinks, quieter line items lose first — not because they are unimportant, but because their benefits are harder to claim as visible wins.

This is not only a rhetorical observation. OECD Health at a Glance 2025 shows that spending on prevention across OECD countries sat around 3% of overall health spending in the decade before COVID-19, rose sharply to about 6% by 2021 as pandemic measures expanded, then fell back toward pre-pandemic levels by 2023 once emergency measures were phased out. Much of the 2021 spike, the OECD notes, reflected time-limited emergency activity rather than long-term planned investment in population health. The uncomfortable implication is explicit in the same analysis: if prevention’s budget share has not structurally improved after a once-in-a-century shock, health systems may remain similarly vulnerable to the next major crisis.

Eurostat’s EU figures tell a related story with an important caution. Preventive healthcare expenditure in the EU fell by 33.6% in current prices from 2022 to 2023, from 0.59% to 0.36% of GDP, and from 5.7% to 3.7% of current healthcare expenditure. Eurostat attributes much of that drop to the fading of COVID-era immunisation programmes — a normalisation of temporary emergency spending, not automatically proof that every euro removed was structural underinvestment. The balanced reading is therefore double: temporary peaks should not be mistaken for a permanently higher prevention floor; and a return to a thin pre-crisis share should not be celebrated as efficiency if core functions were never adequately financed in the first place.

Why financing pressure still matters in Europe

If Europe is wealthier and less dependent on international health aid, why should this debate still matter here? Because European public health is financed mainly through domestic budgets and complementary EU programmes — not through the same aid architecture that now dominates headlines for low-income countries — and because those domestic and EU choices still decide whether prevention, surveillance and preparedness are treated as infrastructure.

Three distinctions matter. First, EU-level public health financing is not the same as national health-system spending. EU4Health is a Union programme for cross-border and shared health priorities; Member States still fund the large majority of hospitals, primary care and local public-health services. Second, healthcare expenditure is not the same as spending on prevention and essential public health functions. In 2023 the EU spent about €1,720 billion on current healthcare — 10.0% of GDP — while preventive healthcare accounted for only 3.7% of that current expenditure and 0.36% of GDP. Third, a fall from pandemic peaks is not automatically the same as structural underinvestment. Some of the 2022–2023 decline in European prevention spending reflects the ending of temporary emergency programmes; the harder question is whether Europe used the crisis to raise its lasting prevention floor, or merely rode a temporary spike back down.

The EU-level signal is concrete. The clearest official arithmetic for the 2021–2027 revision comes from Council documentation: the EU4Health envelope started at €5.775 billion — often rounded to about €5.8 billion — and was reduced by €1 billion when the multiannual financial framework was revised. After related agency adjustments, the overall envelope stands at about €4.56 billion, commonly rounded to around €4.6 billion. Some European Commission public pages summarise nearby figures — an initial budget of about €5.3 billion reduced to about €4.4 billion after the same MFF revision — reflecting the same programme cut under different presentation and rounding conventions. The redeployed funds went to other Union priorities, including support linked to Ukraine, migration pressures, global partnerships and emergencies. That is a legitimate political choice under fiscal constraint. It is also a reminder that even after a pandemic, shared European health capacity competes with other urgent claims — and that programme cuts from 2025 onwards can thin the very preparedness and prevention instruments governments said they wanted to strengthen.

Europe is not one financing environment. Eurostat’s 2023 data show preventive healthcare ranging from 5.2% of current healthcare expenditure in the Netherlands to 0.9% in Malta and 1.3% in Romania, with Poland at 1.7% and the EU average at 3.7%. Per inhabitant, the Netherlands spent about €304 on preventive healthcare against about €12 in Romania — roughly a 25-fold gap in euro terms. Germany and the Netherlands also led relative to GDP. Those gaps matter because ageing populations, workforce shortages, chronic disease, climate-related health threats and future outbreak risk are European problems — but countries enter them with very different prevention floors and institutional capacity.

Preventive healthcare share of current healthcare expenditure in 2023: Netherlands 5.2%, EU average 3.7%, Poland 1.7%, Romania 1.3%, Malta 0.9%.

Netherlands

5.2%

EU average

3.7%

Poland

1.7%

Romania

1.3%

Malta

0.9%

Source: Eurostat, Preventive health care expenditure statistics (2023 data). Shares of current healthcare expenditure (SHA).

WHO/Europe’s recent regional agendas point in the same direction without pretending every country faces identical fiscal space. The Region’s Preparedness 2.0 strategy emphasises sustainable financing and dedicated contingency mechanisms for emergencies. The Second European Programme of Work for 2026–2030 calls for rebalancing spending toward cost-effective public health and primary care, and is frank that NCD prevention remains chronically underfunded even where treatment needs are large. WHO Europe has also underlined severe financial constraints facing countries amid ageing, cost-of-living pressure and competing transitions. The European lesson is therefore not that “Europe is running out of health money” in the same way aid-dependent systems are. It is that wealthy systems can still underfund the functions whose success is least visible — and then rediscover their value only when something goes wrong.

Programmes are not the same as institutions

Across both aid-dependent and high-income settings, the financing model matters as much as the funding volume. Funding a named disease programme can buy medicines, campaigns and short-term results. Sustaining a national public health institute, a laboratory network, a trained workforce, interoperable data systems and a legal mandate for essential public health functions buys something different: the capacity to keep working when the next threat is not the one the last budget line was written for.

In September 2026, WHO reported that more than 120 countries had identified building institutional capacity to deliver essential public health functions as a medium-to-high priority for WHO support. The same update was frank about the financing pattern behind the vulnerability: health-sector budgets remain insufficient and largely skewed towards curative services, while allocation towards essential public health functions is typically donor-driven and function-specific — and therefore does not reliably build sector-wide capacity. Europe’s version of the same problem is often less about donors and more about project cycles, temporary crisis envelopes and political preference for visible care over quieter prevention. The result can look different on a spreadsheet and similar in practice: fragmented capacity that thins when the special funding ends.

Who is most exposed when funding contracts

Exposure remains uneven. Globally, the World Bank’s projections concentrate risk where external financing still covers a large share of health expenditure and fiscal space to replace it quickly is limited. In Europe, exposure is shaped less by aid dependence and more by thin prevention floors, workforce constraints, and the political ease of protecting hospitals while deferring public-health investment. Within countries, the human cost falls first on people already depending on continuous outreach and public programmes — children due for routine immunisation, older adults needing heat- and chronic-disease prevention, communities near outbreak-prone settings, and workers whose posts disappear when a grant or temporary package ends.

A balanced account has to say what financing pressure is not. It is not proof that every cut destroys capacity. Ending a redundant parallel project, consolidating overlapping surveillance tools, or closing a temporary emergency campaign after its purpose has passed can be responsible public finance. The line that matters is whether the decision leaves countries with weaker ability to prevent disease, detect threats early, protect vulnerable groups and respond when the next shock arrives.

What sustainable public health financing should protect

The current squeeze reveals a valuation problem as much as a budget problem. Societies still find it easier to pay for treatment after harm is visible than to finance the quieter machinery that keeps harm smaller. Global aid cuts show how quickly donor-dependent capacity can thin. European data show that wealth does not automatically translate into a durable prevention floor. In both settings, the financing model matters: short project money is not a substitute for institutions, laboratories, workforce posts and domestic budget lines that outlast the news cycle.

What should be protected is not every legacy project line. It is the institutional core: surveillance that runs in quiet years; vaccination systems that do not pause between campaigns; workforce posts that outlast a grant; laboratories and data systems that serve more than one disease; health promotion and NCD prevention that are not endlessly postponed; and domestic — and, where relevant, European — budget commitments that treat essential public health functions as infrastructure rather than optional extras. Rebuilding that capacity after it has been hollowed out is slower, costlier and more politically painful than maintaining it. The money is not “running out” in an absolute sense. The margin for resilient public health is. The practical test for the next few years is whether financing choices protect that margin — or wait until the next visible crisis makes the bill unavoidable.

Sources & further reading

1. OECD — ODA projections for 2026 and the near-term (June 2026)
2. OECD — Health at a Glance 2025: health expenditure on prevention and primary healthcare
3. WHO — Guidance to address drastic global health financing cuts (3 November 2025)
4. WHO — Countries move to strengthen public health institutions and services amid mounting pressures (14 September 2026)
5. World Bank — At a Crossroads: Prospects for Government Health Financing Amidst Declining Aid (GRPH, November 2025)
6. Eurostat — Preventive health care expenditure statistics (2023 data)
7. Eurostat — 10% of the EU’s GDP went to healthcare in 2023
8. European Commission (DG SANTE) — EU4Health programme 2021–2027 overview (envelope after MFF revision)
9. Council of the European Union — EU4Health / MFF revision envelope reduction (ST 15969/2025)
10. European Commission — Proposal COM(2024) 100: MFF mid-term revision and EU4Health adjustment
11. WHO/Europe / European Observatory — Financing for health system transformation (Policy brief 59, 2024)